Aprea Therapeutics, Inc.
For the period ended Jun 16, 2026. Filed Apr 30, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 16, 2026 · Filed Apr 30, 2026
Contents
COMPENSATION PROGRAM
The table below depicts our 2025 compensation program for our non-employee directors and was determined after considering reports previously provided by Pay Governance with respect to prior years’ director compensation programs.
| | | | |
|---|---|---|---|
| Compensation Elements – Non-Employee Director Compensation Program | |||
| Cash | | | |
| Annual Cash Retainer | | $40,000 | |
| Lead Independent Director Retainer | | $20,000 | |
| Annual Committee Chair Retainer | | | |
| Audit | | $7,500 | |
| Compensation | | $5,000 | |
| Nominating and Corporate | | | |
| Governance | | $4,000 | |
| Research and Development | | $4,000 | |
| Committee Member Retainer | | | |
| Audit | | $7,500 | |
| Compensation | | $6,000 | |
| Nominating and Corporate | | | |
| Governance | | $4,000 | |
| Research and Development | | $4,000 | |
| Equity | | | |
| Initial Equity Grant | | | Up to $185,000 (targeted value on the grant date) in stock options vesting in three equal annual installments subject to continued service on the Board. |
| Annual Equity Retainer | | | Up to $150,000 (targeted value on the grant date) in stock options (80%) and RSUs (20%), each vesting on the first anniversary of the date of grant and granted immediately following the annual meeting of stockholders. The Compensation Committee makes a determination on the target dollar value for the annual equity retainer for directors for each fiscal year, but the target dollar value will not exceed $150,000. |
| Given the trading price of our common stock, we made a determination to calibrate the annual equity retainer for 2025 in the context of market, executive grant positioning and aggregate share usage constraints. Thus, for 2025 we did not award the full targeted value of the annual equity retainer. The approximate value of the annual equity retainer for 2025 was $7,248. | |||
Our non-employee directors are also reimbursed for their business-related expenses incurred in connection with attendance at Board and Committee meetings and related activities. Our only employee director, Dr. Gilad, did not receive any compensation for his service on the Board. Please see the 2025 Summary Compensation Table for a summary of the compensation received by Dr. Gilad as our President and Chief Executive Officer in 2025.
| | |
|---|---|
| | 33 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.